| Name | Title | Contact Details |
|---|
Transcriptic is a very small company. We like it that way. Our work culture is an unstructured environment where you can do your best work supported by a group of your peers. Everyone sets their own goals, and everyone is empowered to think creatively. We work hard and we focus, but we don`t do all-nighters or heroic pushes. Grinding yourself into the ground is a fast way to introduce bugs. Life science demands precision; we take our time and we get it right. We use commercial-off-the-shelf solutions when they`re available, and we aren`t afraid to open them up to get to more exacting standards—and if we can`t find it, we build it. We`re completely devoted to solving Transcriptic`s challenges as cleverly as possible to build solid, reliable, intelligent solutions.
Xcellerex is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BlossomHill Therapeutics is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.
TOLMAR is a northern Colorado based pharmaceutical research, development, manufacturing and commercial operations company. TOLMAR develops and manufacturers both proprietary and generic pharmaceutical products with specific focus in therapeutic areas of dental, dermatology, and oncology. TOLMAR provides our customers with a competitive and sustainable combination of product development and commercial services. Our strengths include a proven development, clinical, regulatory and manufacturing infrastructure with highly trained and experienced staff. Several of our marketed products are still in an early stage growth mode.
Founded in Finland in 2000, Nexstim is the world leader in Navigated Brain Stimulation (NBS) with image-guided Transcranial Magnetic Stimulation (TMS). The company is committed to improving the quality of life of patients. Nexstim has pioneered the technology for brain diagnostics with the Navigated Brain Stimulation (NBS) System as the first and only FDA-cleared and CE-marked navigated TMS (nTMS) device for pre-surgical mapping of the motor and speech cortices. The advanced technology providing navigation to TMS has led NBS to be recognized as the emerging standard for pre-operative direct functional mapping. Nexstim initiated its two year multicenter clinical trial on the therapeutic effects of nTMS for stroke rehabilitation in June 2014 with Navigated Brain Therapy